Tempus
tempus.com
AI-enabled precision medicine and data platform.
Quick Information
- Category:
- Healthcare
- Pricing:
- Contact Sales
- Platforms:
- Web, Clinical lab services
- Free Plan:
- No
- Last Verified:
- October 2026
What Is Tempus?
Tempus is an AI-enabled precision medicine company that combines genomic testing with a large clinical and molecular data platform. Its oncology tests include the DNA-based xT, the liquid biopsy xF and the RNA-based xR. In its second quarter of 2026 results, the company said the FDA had approved xT Tumor Only, which it expects to move tissue testing to ADLT pricing. Tempus is publicly traded and reports two main revenue areas: genomics, covering oncology and hereditary testing, and data and services, which licenses de-identified datasets and analytics to life sciences partners.
The numbers show real scale. Full-year 2025 revenue was about $1.27 billion, with diagnostics near $955 million and data and applications around $316 million. Second quarter 2026 revenue was $382.5 million, up 22% year over year, and the company guided to $1.595 billion to $1.605 billion for 2026. Tempus also bought digital pathology company Paige for about $81 million and launched Paige Predict. Pricing for tests and data is not public, since tests are billed through physicians and payers and data deals are negotiated individually. Some product details, such as Tempus One, were not confirmed in the sources found.
Tempus fits oncologists, cancer centres and pharma teams that want genomic testing and real-world data under one roof. Related tools in the Healthcare tools directory include PathAI and Recursion.
What Can You Use Tempus For?
Tumor genomic profiling
DNA and RNA tests to guide cancer treatment decisions.
Liquid biopsy
xF blood-based testing.
Pharma data licensing
Datasets and analytics for drug development.
Digital pathology
Paige tools add AI slide analysis.
Tempus Features
- xT, xF and xR assays — DNA tumor, liquid biopsy and RNA testing.
- Data and services — De-identified clinical and molecular datasets.
- Paige Predict — Biomarker prediction built on Paige's foundation model.
- FDA-approved xT Tumor Only — Approval reported in Q2 2026 results.
Who Is Tempus For?
- Oncologists and cancer centres — Order genomic tests to guide therapy.
- Pharma and biotech — License real-world data for research.
Tempus Pros & Limitations
What We Like
- Large scale: about $1.27B revenue in 2025
- Combines testing, data and AI in one company
- Expanded into digital pathology via Paige
Limitations
- No simple public price list
- Complex product line spread across tests and data
- Some product details were not confirmed in the sources found
Tempus Pricing
| Plan | Price | Main Features |
|---|---|---|
| Clinical testing | Billed through physicians and payers | xT, xF and xR oncology assays, hereditary testing |
| Data and services | Custom | De-identified datasets and analytics for life sciences |
Pricing was last verified October 2026. Check the official website for the latest pricing.
AI Listing Jungle Ranking
- Global Rank:
- #859
- Overall Score:
- 48.6/100
- Monthly Users:
- –
- Rank Change:
- ▼ 223
This ranking reflects AI Listing Jungle's own independent scoring methodology and is not an endorsement by Tempus or its company. How Our Rankings Work
Frequently Asked Questions
What does Tempus do?
It provides genomic testing and a data platform that uses AI for precision medicine, mainly in oncology.
How big is Tempus?
Full-year 2025 revenue was about $1.27 billion, and 2026 guidance is $1.595 to $1.605 billion.
Did Tempus buy Paige?
Yes, for about $81 million.
How much do Tempus tests cost?
They are billed through physicians and payers, so there is no simple list price.
Our Take
Tempus is one of the few AI health companies operating at real commercial scale, with testing revenue backing its data business.
Pricing depends on payers and contracts, so expect an enterprise-style evaluation.
Tempus Alternatives
Tempus Comparisons
Ready to try Tempus?
Visit the official website to get started.
Visit Official WebsiteAI Listing Jungle is an independent AI tools directory. Product names, logos, and trademarks belong to their respective owners.